Winona Clinical Gaps and Limitations: What This Telehealth HRT Platform Misses

What Winona Actually Offers

Winona operates as a direct-to-consumer telehealth platform that prescribes FDA-approved hormone therapy for women experiencing menopause symptoms. The core formulary includes oral and transdermal estradiol, oral micronized progesterone (generic Prometrium), and combination regimens. Visits are asynchronous in most states, meaning patients complete an intake questionnaire and a provider reviews it without a live video consultation.

This model has clear advantages for access. Women in rural areas or states with limited menopause specialists can obtain prescriptions without a 4-to-6-month wait for an in-person appointment. The North American Menopause Society (now The Menopause Society) has noted that only about 20% of OB-GYN residency programs provide menopause-specific training [1]. That gap in trained clinicians makes telehealth platforms a reasonable entry point.

The problem is what happens after that entry point. Winona's clinical infrastructure omits several steps that guideline-concordant menopause care considers standard. These omissions matter because HRT, while safe for most women within 10 years of menopause onset, carries real risks when prescribed without adequate baseline assessment or follow-up [2].

The Lab Monitoring Gap

Winona does not require baseline laboratory testing before initiating hormone therapy. This is a significant departure from standard clinical practice. The Endocrine Society's 2015 Clinical Practice Guideline on menopausal HRT recommends assessing cardiovascular risk factors, including a fasting lipid panel, fasting glucose, and blood pressure measurement, before starting estrogen therapy [3].

Why does this matter? Oral estradiol undergoes hepatic first-pass metabolism, which raises triglycerides by approximately 15-25% in some women [4]. A woman with undiagnosed hypertriglyceridemia (triglycerides above 500 mg/dL) started on oral estradiol faces increased pancreatitis risk. Transdermal estradiol avoids first-pass metabolism and does not raise triglycerides, but Winona's intake process may not flag this distinction adequately without lab data.

Hepatic function testing is also absent. The FDA labeling for estradiol products lists active liver disease as a contraindication [5]. An asynchronous questionnaire asking "do you have liver problems" depends entirely on patient awareness of subclinical conditions.

Thyroid function screening deserves mention as well. Hypothyroidism and menopause share overlapping symptoms: fatigue, weight gain, mood changes, and cognitive fog. Without TSH testing, a provider might attribute hypothyroid symptoms to menopause and prescribe estrogen when levothyroxine is what the patient actually needs. A 2019 cross-sectional analysis found that 15.3% of perimenopausal women presenting with "menopause symptoms" had previously undiagnosed thyroid dysfunction [6].

Formulary Limitations That Affect Clinical Outcomes

Winona's formulary is narrower than what evidence-based menopause care supports. Several FDA-approved options are absent from the platform.

No vaginal DHEA (prasterone). The FDA approved intravaginal prasterone (Intrarosa) in 2016 for moderate-to-severe dyspareunia caused by GSM [7]. The NCGS trial (N=325) demonstrated statistically significant improvement in vaginal dryness, pain during intercourse, and vaginal pH compared to placebo at 12 weeks. For women whose primary complaint is GSM rather than vasomotor symptoms, prasterone may be more appropriate than systemic estrogen. Winona does not offer it.

No bazedoxifene/conjugated estrogens (Duavee). This tissue-selective estrogen complex is the only approved HRT option that provides endometrial protection without a progestogen [8]. For women who experience intolerable side effects from progesterone (bloating, mood changes, breakthrough bleeding), Duavee represents a clinically meaningful alternative. Its absence from Winona's formulary removes an option that roughly 10-15% of HRT patients might benefit from based on progesterone intolerance rates reported in the PEPI trial [9].

No testosterone. The Global Consensus Position Statement on testosterone therapy for women (2019) endorsed low-dose testosterone for postmenopausal hypoactive sexual desire disorder (HSDD), citing a meta-analysis of 36 RCTs (N=8,480) showing a mean increase of 0.85 satisfying sexual episodes per month versus placebo [10]. While no FDA-approved testosterone product for women exists in the U.S., compounded formulations are widely prescribed off-label by menopause specialists. Winona excludes this entirely.

No ospemifene (Osphena). FDA-approved for moderate-to-severe dyspareunia, ospemifene is a selective estrogen receptor modulator that works systemically without exogenous estrogen [11]. It is an option for women with estrogen-receptor-positive breast cancer history who cannot use vaginal estrogen. Winona does not carry it.

The Asynchronous Visit Problem

Asynchronous consultations work well for straightforward clinical scenarios. Menopause care is often not straightforward.

Consider a 52-year-old woman with vasomotor symptoms, a BMI of 34, a first-degree relative with breast cancer, and a personal history of migraine with aura. Each of these factors changes the risk-benefit calculus for HRT in specific ways. Migraine with aura increases stroke risk with oral estrogen but not necessarily with transdermal formulations [12]. Obesity alters estradiol absorption from patches. Family history of breast cancer does not contraindicate HRT per the 2022 Menopause Society Position Statement, but it requires a more nuanced discussion than a checkbox can provide [2].

Dr. Stephanie Faubion, Medical Director of The Menopause Society, has stated: "Menopause hormone therapy is not one-size-fits-all. The type, dose, route, and timing all matter, and these decisions require a clinician who understands the nuances" [13]. An asynchronous questionnaire reviewed by a provider who may see hundreds of intakes per week structurally limits how much nuance each case receives.

The 2022 Menopause Society Position Statement specifically recommends that HRT be "individualized to identify the most appropriate type, dose, formulation, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks" [2]. This level of individualization requires dialogue, not data entry.

Reassessment and Duration-of-Use Concerns

The FDA labeling for all systemic estrogen products states that therapy should use "the lowest effective dose for the shortest duration consistent with treatment goals" [5]. Both the Menopause Society and the Endocrine Society recommend reassessment at least annually.

Winona's subscription model creates a structural incentive that runs counter to reassessment. Automatic refills, while convenient, can lead to prolonged therapy without a clinical check-in. A woman who started HRT at 51 for hot flashes may still be receiving the same regimen at 61, when the risk-benefit ratio has shifted considerably.

The Women's Health Initiative (WHI) data showed that combined estrogen-progestin therapy increased breast cancer risk by 26% (HR 1.26 to 95% CI 1.00-1.59) after a mean of 5.6 years of use [14]. The absolute risk was small (8 additional cases per 10,000 women-years), but it is not zero. For women beyond 10 years of menopause onset or over age 60, the cardiovascular risks of initiating HRT also increase based on WHI subgroup analyses [15].

Annual reassessment should include: review of symptom burden, attempt at dose reduction, updated breast cancer risk assessment, blood pressure measurement, and discussion of continuing versus tapering therapy. A platform that ships refills on autopilot without mandating these steps fails the reassessment standard.

How Winona Compares to Guideline-Concordant Care

The gap between Winona and a board-certified menopause specialist (MSCP credential from The Menopause Society) is not about whether the drugs prescribed are legitimate. They are. Winona prescribes FDA-approved medications through licensed pharmacies. The gap is in clinical thoroughness.

An MSCP-credentialed provider would typically perform or order baseline labs (CBC, CMP, lipid panel, TSH, and sometimes estradiol/FSH levels), conduct a breast exam and pelvic exam or confirm recent results, assess cardiovascular risk using the ASCVD risk calculator, discuss the full formulary including testosterone and vaginal options, schedule a 3-month follow-up to assess response, and conduct annual reassessment with consideration of dose reduction [2] [3].

Winona does not replicate this workflow. The question is whether the increased access Winona provides compensates for the clinical depth it sacrifices. For a healthy, low-risk 48-year-old with classic vasomotor symptoms and no complicating factors, Winona may deliver adequate care. For complex patients, the gaps become clinically relevant.

The Cost-Access Tradeoff

Winona charges approximately $49-$199 per month depending on the regimen, with no insurance billing. Generic oral estradiol (1 mg) costs roughly $4-$15/month through GoodRx at a retail pharmacy with a standard prescription. Estradiol patches (generic Vivelle-Dot) run $30-$60/month at retail.

The price differential means a woman paying Winona $149/month for an estradiol patch plus progesterone could obtain the identical medications for $40-$80/month through her insurance or a GoodRx coupon with a prescription from her primary care provider. The Winona premium covers the platform's telehealth consultation, but for ongoing refills, that premium accumulates. Over 12 months, the difference can exceed $800.

For women without insurance or without a provider willing to prescribe HRT (a real barrier given the training gap mentioned earlier), Winona's premium buys access. That access has value. But patients should understand they are paying a convenience surcharge, not receiving a superior clinical product.

The Legitimacy Question

Is Winona legit? Yes, in the regulatory sense. Winona employs licensed physicians and nurse practitioners, prescribes FDA-approved medications, and uses licensed pharmacies. The platform is not a scam.

But "legit" and "optimal" are different standards. A platform can be fully licensed while still delivering care that falls below what current evidence supports. The clinical gaps outlined above do not make Winona fraudulent. They make it incomplete.

The NAMS/Menopause Society maintains a directory of MSCP-credentialed providers at menopause.org [16]. Women using Winona should consider whether their clinical situation warrants the more comprehensive evaluation these specialists provide, particularly if they have risk factors for cardiovascular disease, breast cancer, or venous thromboembolism. The Endocrine Society recommends that women at elevated VTE risk use transdermal rather than oral estrogen, a routing decision that requires clinical judgment beyond what an intake form captures [3].

Women currently using Winona who want to verify their regimen is appropriate can request their records from the platform and bring them to an in-person provider for a one-time comprehensive review, then continue telehealth management if the regimen is confirmed as appropriate.